Q-omics provides the consensus-scored VPS11 profile across patient tissues and cancer cell-line models. VPS11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS11 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, VPS11 protein abundance shows 23,155 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where VPS11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS11 survival associations across molecular data types. VPS11 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS11 RNA expression–survival associations across cancer types. High VPS11 expression shows unfavorable associations in LIHC, LUSC and KICH, but favorable associations in KIRC, KIRP and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS11 RNA expression.
This table summarizes VPS11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS11 shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, LIHC, KIRP and COAD. The KIRC box plot shows higher VPS11 RNA expression in tumor versus normal tissue (log2 FC = +0.759, t-test p < 0.001).
This table shows molecular features associated with VPS11 in patient tissues and cancer cell lines. In patient samples, VPS11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
